Assignee
QILU PHARMACEUTICAL CO LTD
CN·9 granted patents·10 pending applications·56 citations·filing 2015–2025
Top patents by PatentIndex Score
19 records- 0192US10253030B2Crystal form, preparation method and intermediate of dihydropyrido ring compoundQILU PHARMACEUTICAL CO LTD·Filed 2016·Granted Apr 9, 2019·25 cites·26 claims
- 0291US9938301B2Dihydropyrimido fused ring derivative as HBV inhibitorQILU PHARMACEUTICAL CO LTD·Filed 2015·Granted Apr 10, 2018·27 cites·18 claims
- 0381US12415853B2Antibody against claudin 18A2 and use thereofQILU PHARMACEUTICAL CO LTD·Filed 2020·Granted Sep 16, 2025·2 cites·18 claims
- 0476US12240888B1Composition comprising aflibercept and a variant thereof, and related methods and usesQILU PHARMACEUTICAL CO LTD·Filed 2024·Granted Mar 4, 2025·0 cites·5 claims
- 0575US10053477B2Spirocyclic aryl phosphorus oxide and aryl phosphorus sulfideQILU PHARMACEUTICAL CO LTD·Filed 2015·Granted Aug 21, 2018·2 cites·13 claims
- 0672US2025333478A1Composition comprising aflibercept and a variant thereof, and related methods and usesQILU PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
- 0767US2025195426A1High drug-loading fulvestrant pharmaceutical composition and preparation method thereofQILU PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
- 0863US2025376525A1Pharmaceutical composition comprising mixed antibody of anti-ctla4 and anti-pd1 and therapeutic use thereofQILU PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0962US11180501B2Crystal form of β-lactamase inhibitor and preparation method thereforQILU PHARMACEUTICAL CO LTD·Filed 2018·Granted Nov 23, 2021·0 cites·16 claims
- 1059US2024216402A1Pharmaceutical composition, and preparation method therefor and application thereofQILU PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1156US2024180823A1Inhalation spray of semaglutide and preparation method thereofQILU PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1256US2025381268A1Pharmaceutical composition comprising anti-ctla4 and anti-pd1 antibody mixture and therapeutic use thereofQILU PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1351US10662198B2Polymorphic form of compound, preparation method and use thereofQILU PHARMACEUTICAL CO LTD·Filed 2018·Granted May 26, 2020·0 cites·20 claims
- 1451US2026097042A1Compound emulsion, preparation method therefor, and use thereofQILU PHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
- 1549US2023219986A1Novel aminopyrimidine egfr inhibitorQILU PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 1649US2024308990A1Crystal form of entrectinib and preparation method thereforQILU PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1749US2024034743A9Tricyclic compounds as egfr inhibitorsQILU PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 1843US12540345B2Composition comprising aflibercept and a variant thereof, and related methods and usesQILU PHARMACEUTICAL CO LTD·Filed 2025·Granted Feb 3, 2026·0 cites·6 claims
- 1935US10738051B2β-lactamase inhibitorsQILU PHARMACEUTICAL CO LTD·Filed 2017·Granted Aug 11, 2020·0 cites·7 claims
Join the waitlist — get patent alerts
Get an alert when QILU PHARMACEUTICAL CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →